Home » Topics » Regulatory » EMA

EMA
RSS

EMA's CHMP supports expanding Nplate indication

Nov. 13, 2017

FDA gives orphan status to Achillion's ACH-4471 for PNH

Nov. 8, 2017

Pegfilgrastim biosimilar from Sandoz accepted for EMA review

Oct. 31, 2017

VBL Therapeutics' VB-111 granted orphan medicinal product status in E.U.

Oct. 23, 2017

EMA grants orphan drug designation to G-100 for the treatment of follicular non-Hodgkin's lymphoma

Oct. 20, 2017

EMA grants orphan drug designation to Conatus' IDN-7314 for primary sclerosing cholangitis

Oct. 19, 2017

Ignyta's entrectinib obtains PRIME designation from EMA

Oct. 18, 2017

EMA's CHMP supports expansion of marketing authorization for Zytiga

Oct. 16, 2017

EMA accepts Imfinzi MAA for locally advanced unresectable NSCLC

Oct. 9, 2017

EMA accepts Cinfa's MAA for biosimilar pegfilgrastim B-12019

Oct. 6, 2017

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 20, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
Novel caspase-2 inhibitor shows in vivo neuroprotective effects
BioWorld Science
Caspase-2-mediated cleavage of tau at Asp314 generates a neurotoxic fragment, Δtau314, that drives early synaptic dysfunction in Alzheimer’s disease (AD) and...